Re: “No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir” by Calza et al.
Restricted accessLetterFirst published online May, 2021
Re: “No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir” by Calza et al.
CalzaL, BorderiM, ColangeliV, et al.: No significant changes in weight and body fat mass in suppressed HIV-infected patients switched to dual combination lamivudine plus dolutegravir or raltegravir. AIDS Res Hum Retroviruses 2020 [Epub ahead of print]. DOI: 10.1089/AID.2020.0117.
2.
CicculloA, D'AvinoA, LassandroAP, et al.: Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: Preliminary results from clinical practice. Infez Med, 2018; 26:336–340.
3.
PetrakisV, PanagopoulosP, PapachristouS, et al.: Tenofovir alafenamide fumarate therapy for HIV treatment: Cardiometabolic and renal safety. AIDS Res Hum Retroviruses 202036:697–702.
4.
CicculloA, BaldinG, CapettiA, et al.: Cohort profile: The observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE). BMJ Open, 2019; 9:e029960.
